Astria Therapeutics Profit Margin

Astria Therapeutics (ATXS) currently reports a profit margin of -17567.99% as of September 2025. That is below the Healthcare sector average of 13.89%. Use the charts on this page to explore Astria Therapeutics's profit margin history and peer comparisons.

Astria Therapeutics's profit margin of -17567.99% is lower than the Healthcare sector average of 13.89%. That is roughly 126624.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Astria Therapeutics's current -17567.99% should be judged against Healthcare norms (sector average: 13.89%) and against ATXS's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -17567.99%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 13.89%. From there, open related valuation or income-statement pages for Astria Therapeutics, and consider following ATXS for alerts when major investors trade the stock.

Astria Therapeutics is classified in the Healthcare sector. On profit margin, it currently shows -17567.99% versus a sector average near 13.89%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ATXS with unrelated industries.